Paolo A. Ascierto, MD

Director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy
Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale," Naples, Italy, United States

Presentation(s):

• 63: Adjuvant therapy with nivolumab versus placebo in patients with resected stage IIB/C melanoma (CheckMate 76K)

  Friday, March 24, 2023
  11:24 AM – 11:34 AM

  Disclosure information not submitted.

• 54: Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Tumor Location in the Phase 3 KEYNOTE-716 Study

  Friday, March 24, 2023
  1:49 PM – 2:01 PM

  Disclosure information not submitted.